@article{5f72ab6a76ea460eb04231e6d4c4514c,
title = "Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis: NeuroImage: Clinical",
abstract = "Background and aims: Considering the great heterogeneity of amyotrophic lateral sclerosis (ALS), the identification of accurate prognostic predictors is fundamental for both the clinical practice and the design of treatment trials. This study aimed to explore the progression of clinical and structural brain changes in patients with ALS, and to assess magnetic resonance imaging (MRI) measures of brain damage as predictors of subsequent functional decline. Methods: 50 ALS patients underwent clinical evaluations and 3 T MRI scans at regular intervals for a maximum of 2 years (total MRI scans = 164). MRI measures of cortical thickness, as well as diffusion tensor (DT) metrics of microstructural damage along white matter (WM) tracts were obtained. Voxel-wise regression models and longitudinal mixed-effects models were used to test the relationship between clinical decline and baseline and longitudinal MRI features. Results: The rate of decline of the ALS Functional Rating Scale revised (ALSFRS-r) was significantly associated with the rate of fractional anisotropy (FA) decrease in the body of the corpus callosum (CC). Corticospinal tract (CST) and CC-body alterations had a faster progression in patients with higher baseline ALSFRS-r scores and greater CC-body disruption at baseline. Lower FA of the cerebral peduncle was associated with faster subsequent clinical progression. Conclusions: In this longitudinal study, we identified a significant association between measures of WM damage of the motor tracts and functional decline in ALS patients. Our data suggest that a multiparametric approach including DT MRI measures of brain damage would provide an optimal method for an accurate stratification of ALS patients into prognostic classes. {\textcopyright} 2020 The Author(s)",
keywords = "Amyotrophic lateral sclerosis, Cortical thickness, Diffusion tensor MRI, Prognosis, Structural MRI, adult, amyotrophic lateral sclerosis, Article, brain damage, cerebral peduncle, clinical article, clinical evaluation, clinical outcome, clinical practice, contrast, controlled study, corpus callosum, cortical thickness (brain), diffusion tensor imaging, disease association, disease exacerbation, disease severity, female, fractional anisotropy, functional disease, human, longitudinal study, male, priority journal, pyramidal tract, rating scale, white matter",
author = "E.G. Spinelli and N. Riva and P.M.V. Rancoita and P. Schito and A. Doretti and B. Poletti and {Di Serio}, C. and V. Silani and M. Filippi and F. Agosta",
note = "Cited By :1 Export Date: 11 March 2021 Correspondence Address: Agosta, F.; Neuroimaging Research Unit, Via Olgettina, 60, Italy; email: agosta.federica@hsr.it Funding details: -2010-2313220, -2011-02351193, RF-2010–2313220, RF-2011–02351193 Funding details: Novartis Funding details: Teva Pharmaceutical Industries Funding details: Biogen Idec Funding details: Takeda Pharmaceutical Company Funding details: Sanofi Genzyme Funding details: Roche Italia Funding details: Cytokinetics, CYTK Funding details: AveXis Funding details: European Research Council, ERC, 02351193, 2313220, RF-2010 Funding details: Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica, AriSLA Funding text 1: This study was partially supported by the Italian Ministry of Health (grants #RF-2010-2313220 and #RF-2011-02351193). Funding text 2: F. Agosta is Section Editor of NeuroImage: Clinical; has received speaker honoraria from Novartis , Biogen Idec and Philips ; and receives or has received research supports from the Italian Ministry of Health, AriSLA ( Fondazione Italiana di Ricerca per la SLA ), and the European Research Council. Funding text 3: The authors thank the patients and their families for the time and effort they dedicated to the research. This study was partially supported by the Italian Ministry of Health (grants #RF-2010-2313220 and #RF-2011-02351193). E.G. Spinelli, N. Riva, PMV Rancoita, A. Doretti, B. Poletti, and C. Di Serio report no disclosures. V. Silani is in the Editorial Board of Amyotroph Lateral Sclerosis, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology; received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, and Italfarmaco; and receives or has received research supports from the Italian Ministry of Health, AriSLA (Fondazione Italiana di Ricerca per la SLA), and E-Rare Joint Transnational Call. M. Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). F. Agosta is Section Editor of NeuroImage: Clinical; has received speaker honoraria from Novartis, Biogen Idec and Philips; and receives or has received research supports from the Italian Ministry of Health, AriSLA (Fondazione Italiana di Ricerca per la SLA), and the European Research Council. Supported by: Italian Ministry of Health (RF-2010?2313220; RF-2011?02351193). Funding text 4: Supported by: Italian Ministry of Health (RF-2010–2313220; RF-2011–02351193).",
year = "2020",
doi = "10.1016/j.nicl.2020.102315",
language = "English",
volume = "27",
journal = "NeuroImage Clin.",
issn = "2213-1582",
publisher = "Elsevier Inc.",
}